January 28, 2026
NV Therapeutics welcomes Jimi Olaghere as Patient-in-Residence & Advisor

NV Therapeutics has appointed Jimi Olaghere, a Casgevy gene therapy recipient, as Patient-in-Residence and Advisor for Q1 2026. This initiative embeds the lived patient experience directly into the R&D phase, ensuring the company’s strategic trajectory is driven by the specific needs of the people for whom gene therapies are engineered, while advancing a core mission of improving global access and health equity.

September 12, 2025
NV Therapeutics signs Sponsored Research Agreement with University College London

Agreement allows NV Therapeutics, Inc. to formalize collaborative research projects with the laboratories of Dr. Adrian Thrasher, Physician and Professor of Pediatric Hematology and Dr. Giorgia Santilli, Associate Professor in Gene Therapy at University College London Great Ormond Street Institute of Child Health (GOSH) in London, the United Kingdom.

July 29, 2025
NV Therapeutics signs Sponsored Research Agreement with UCLA

Agreement allows NV Therapeutics, Inc. to formalize collaborative research projects with the laboratory of Dr. Donald Kohn, Physician and Distinguished Professor of Pediatric Hematology and Oncology at the Broad Stem Cell Research Center, University of California, Los Angeles.

October 7, 2024
NV Therapeutics begins operations at Bakar Bio Labs incubator

NV Therapeutics, Inc. has established laboratory operations at Bakar Bio Labs, a world-class incubator site for life science startups in Berkeley, California. Founded as a partnership between University of California, Berkeley and QB3, the incubator provides a supportive ecosystem for NV Therapeutics to develop their platform technology and therapeutic programs.

September 13, 2024
NV Therapeutics secures Seed Funding from 4BIO Capital

Seed Funding from 4BIO Capital (4BIO Partners LLP), a London, United Kingdom based venture capital firm specializing in early-stage life sciences and advanced therapies, enables NV Therapeutics, Inc. to establish business operations and execute its recruitment and facility build plan.